MLYSMineralys Therapeutics, Inc.
$23.36-41% 1Y
$23.36
$21.9552 weeks$47.33
MLYS in its own filings
Nothing in MLYS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
74
Events found in the filings · across 399 filings · the record starts in 2022
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Dec 1, 2022
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity6 occurrences
- 2024-04-09
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026On August 5, 2026, the Company’s Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company’s new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor.Earnings release · Form 8-K
- Jun 3, 2026On June 3, 2026, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C. (the “Underwriters”), relating to the issuance and sale of 5,660,378 shares of the Company’s …Other event · Form 8-K
- Jun 3, 2026Fourth Amendment to the License Agreement On June 2, 2026, Mineralys Therapeutics, Inc. (the “Company”) entered into a fourth amendment (the “Amendment”) to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025 (the “License Agreement”), between the Company …Material agreement entered · Form 8-K
- May 6, 2026Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Mar 12, 2026Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Mar 9, 2026On March 6, 2026, the FDA notified the Company that its NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs had been accepted.Regulation FD disclosure · Form 8-K
- Jan 6, 2026On January 6, 2026, the Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safety and efficacy of …Regulation FD disclosure · Form 8-K
- Nov 10, 2025Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks